Emzor Pharmaceutical Industries Ltd (Emzor), one of the leading firms in the Nigerian pharmaceutical sector, has announced the successful repayment of its inaugural Series 1 Commercial Paper.

The paper, which was originally issued in November 2024 under its N10 billion Commercial Paper Issuance Programme, the N5.13 billion notes, matured on August 18, 2025, marking a significant milestone in the company’s capital markets journey.

This fulfilment and the continued retention of its investment grade credit rating of A- with a stable outlook (GCR), further reinforces Emzor’s credibility and financial discipline in Nigeria’s investment landscape.

Scaling Up Local API Production with a $23 Million Investment: Emzor has invested in a transformative $23 million API (Active Pharmaceutical Ingredients) plant located in Sagamu, Ogun State—the first of its kind in Sub-Saharan Africa.

This venture is set to bolster Nigeria’s drug self-sufficiency by reducing import reliance and lowering production costs, especially for vital medicines like antimalarials and HIV/AIDS antiretrovirals.

The API Plant is near completion, while it was initially slated for Q1-2024, the timeline has been revised to early 2026, owing to fiscal, monetary, and regulatory complexities.

Despite these pressures, the project is advancing swiftly, with over 90% of civil works completed and critical equipment already installed. The API R&D laboratory has already developed and synthesized five antimalarial API’s in anticipation of full-scale production.

Demonstrating a steadfast commitment to quality and consumer safety, Emzor has rolled out an advanced ERP, Oracle, as well as a track-and-trace software system across its supply chain.

These solutions support lean manufacturing, tighten inventory management, and strengthen market surveillance, helping to eliminate substandard and counterfeit medications—especially in underserved areas.

Promoting Manufacturing Resilience and Regional Outreach: mAt a recent ECOWAS@50 summit in Lagos, Emzor reaffirmed its pivotal role in enhancing medicine security across the continent.

Notably, the company now has over 200 registered products manufactured across several factory sites, and distributes to all Nigerian states and to West Africa, including direct exports to Liberia and Sierra Leone.

Talking about advantages from government policies in bolstering local pharma production,

Emzor is one of the beneficiaries of a landmark policy move by Nigeria’s government, which exempts pharmaceutical raw materials from import duties and VAT for two years.

This regulatory support aims to stimulate local production, making essential medicines more affordable.

Emzor’s timely repayment of its debut commercial paper underscores its robust financial management, while its strategic initiatives—ranging from cutting-edge infrastructure to digital integrity systems—highlight its leadership in Nigeria’s pharmaceutical evolution.